Avantor, Inc. (AVTR) Business Profile

What it does

Avantor supplies products and services used in scientific research, healthcare and manufacturing. Its customers include biopharmaceutical companies, healthcare providers, universities, government institutions and businesses working with advanced technologies and materials. It supports work from early research through the production of finished treatments and other products.

Through VWR, it distributes laboratory consumables and equipment made by other suppliers, as well as products sold under the VWR label. It also manufactures its own specialty products for life sciences and medical technology applications.

Those products include high-purity chemicals used in research and bioprocessing, pumps and tubing for moving fluids, and customized silicone materials used in human implants. Other offerings range from laboratory supplies and analytical instruments to materials used in manufacturing. Avantor also provides services such as laboratory inventory management, equipment support and assistance with production processes.

Avantor’s business traces part of its legacy to the J.T. Baker Chemical Company. Emmanuel Ligner is president and chief executive officer.

How it makes money

Avantor earns revenue by selling materials and consumables, equipment and instruments, and services. Customers can buy products manufactured by Avantor or products it sources from other suppliers. The majority of its net sales came from offerings the company considers recurring in nature, including supplies that customers use in ongoing laboratory and production work.

In FY2025, Laboratory Solutions sold products and services used in laboratory work, while Bioscience Production served production-oriented applications. Laboratory Solutions generated $4.4 billion of revenue in FY2025, and Bioscience Production generated $2.2 billion. Proprietary products accounted for 52.6% of FY2025 revenue, with third-party products making up the remainder.

Avantor’s product range includes chemicals, laboratory supplies, single-use assemblies and chromatography products, alongside equipment such as filtration systems and freezers. Services include onsite laboratory and production support, procurement and sourcing, and assistance with scaling up biopharmaceutical materials. Some customer contracts include pricing and volume incentives, but customers generally are not required to buy fixed quantities.

Avantor reported a decline in net sales in FY2025 and a return to organic revenue growth in Q3 2026.

The VWR distribution and services and Bioscience and Medtech Products businesses have different margin profiles: Avantor says VWR’s lower gross margin profile and faster growth affected the company’s gross margin in Q3 2026.

Customers and how it sells

Avantor serves customers across biopharma and healthcare, education and government, and advanced technologies and applied materials. Its products are used in research, diagnostics, quality control and manufacturing. The company serves customer locations around the world.

Avantor has longstanding customer relationships. No single end customer accounted for more than 5.00% of net sales in FY2025. Avantor works with customers at early stages of research and development and develops products that can become specified in their approved production processes.

Customers reach Avantor through its sales force, websites and catalogs. Most transactions came through digital channels. Its services staff also work alongside customers, helping with tasks such as procurement, inventory management and laboratory operations.

Avantor sells across the Americas, Europe and AMEA. In Q3 2026, it saw improving demand among North American higher-education and early-stage biotech customers, while its large pharmaceutical and biotech customers continued to invest in research pipelines. Avantor said the market recovery in Europe was lagging the Americas and Asia, with high energy costs and pressure on government funding among the challenges.

Suppliers and costs

Avantor sources third-party products from suppliers around the world as well as making its own products. Its VWR private-label offering enables suppliers to provide products under the VWR label. Supplier contracts vary by geography, duration and product or service, and some include exclusivity provisions.

The company also needs raw materials that meet its quality specifications. Many are sole-sourced because of market or customer demands, making supply dependent on the availability and pricing of those materials and relationships with suppliers. Avantor operates manufacturing facilities around the world and has a network of distribution centers.

Avantor has experienced supply-chain constraints and inflation across its cost categories. Its FY2025 gross profit and margin were affected by lower sales volume, inflation, higher freight costs and the sale of its Clinical Services business. The company has used pricing and productivity measures to address cost pressures.

In Q3 2026, Avantor said inflation continued to affect the business. It also said faster growth in VWR, which has a lower gross margin profile than its production business, put pressure on the company’s gross margin.

Competitive position

Avantor competes in a fragmented market that includes regional and multinational suppliers. Competition varies by product and customer need and involves price, quality, delivery, product range, customization, customer support and online capabilities. Avantor does not name its competitors.

The company combines a distribution channel with proprietary manufacturing. VWR offers products from many suppliers, while Avantor makes specialty materials and equipment under brands including J.T. Baker, Masterflex and NuSil. Its manufacturing and innovation facilities support customized products for regulated, specification-driven applications.

Our reading: customer relationships and products specified in approved production processes offer a meaningful competitive advantage because they place Avantor within customers’ ongoing workflows. The protection is not absolute: customers generally have no obligation to purchase fixed quantities and can stop ordering.

Our reading: the breadth of VWR’s supplier network, digital ordering and onsite services supports its competitive position, although the market remains competitive on price and service. Proprietary know-how and brands also support differentiation, but competitors can develop alternatives or design around intellectual property.

Growth opportunities

Avantor develops products with customers early in their research cycles, with the aim of supporting them through development and commercialization. Its work includes improving purity, performance and packaging, as well as developing products for areas such as cell and gene therapy. The company also plans to continue investing in e-commerce, artificial intelligence tools and its supply chain.

Its Revival program focuses on commercial execution, customer relationships and operations. Avantor has increased manufacturing throughput and developed digital workflows and electronic batch records at key manufacturing sites. It is also using AI in VWR sales tools and in a platform that helps identify product substitutes.

After net sales declined in FY2025, Avantor returned to organic revenue growth in Q3 2026. VWR and Bioscience and Medtech Products both grew organically in the quarter.

Avantor raised its full-year organic revenue growth outlook. It expects to reduce adjusted net leverage by year-end. Under its cost transformation initiative, the company expects run-rate gross savings.

Structural risks

• Customer demand and funding: Customers can stop placing orders and generally have no minimum purchase requirements. Reductions or delays in government research funding could cause universities and other institutions to defer or forgo purchases.

• Supply and operations: Disruptions at manufacturing or distribution centers, or at logistics providers, could delay deliveries and increase costs. Some raw materials are sole-sourced, and suppliers must meet Avantor’s quality and delivery requirements.

• Quality and regulation: High-purity materials and customized products must meet demanding specifications. Defects or quality-control failures could lead to lost sales, higher costs and reputational damage. Compliance with extensive manufacturing and other regulations can also be costly.

• Competition and customer changes: Consolidation among biopharma and healthcare customers can concentrate purchasing decisions and increase pricing pressure. Customers may also buy directly from Avantor’s suppliers or develop products themselves.

• Cost transformation and financing: Avantor may not achieve its expected restructuring savings on time or at all. It relies on operating cash flow and credit facilities for funding, and much of its long-term financing comes from debt.

• Technology and cyberattacks: Information-system failures or security breaches affecting Avantor or its service providers could disrupt orders, expose data, increase costs and lead to litigation or regulatory action.

Bottom line

Our reading

Our reading: Avantor combines a broad laboratory distribution business with proprietary products used in regulated research and production, supported by long customer relationships and recurring demand. Its exposure includes customers’ research budgets, manufacturing and supply reliability, and the lower margin profile of its distribution business. The return to organic growth in Q3 2026 followed a sales decline in FY2025, while cost pressures and debt remain important considerations.